GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » EPS (Diluted)

Maat Pharma (XPAR:MAAT) EPS (Diluted) : €-1.70 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma EPS (Diluted)?

Maat Pharma's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.90. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.70.

Maat Pharma's EPS (Basic) for the six months ended in Dec. 2023 was €-0.90. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.70.

Maat Pharma's EPS without NRI for the six months ended in Dec. 2023 was €-0.90. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.70.

During the past 3 years, the average EPS without NRIGrowth Rate was 30.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Maat Pharma's highest 3-Year average EPS without NRI Growth Rate was 34.20% per year. The lowest was 5.10% per year. And the median was 30.60% per year.


Maat Pharma EPS (Diluted) Historical Data

The historical data trend for Maat Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma EPS (Diluted) Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -5.66 -5.10 -3.70 -1.40 -1.70

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.50 -0.80 -0.60 -0.80 -0.90

Competitive Comparison of Maat Pharma's EPS (Diluted)

For the Biotechnology subindustry, Maat Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maat Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Maat Pharma's PE Ratio falls into.



Maat Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Maat Pharma's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-19.717-0)/11.365
=-1.73

Maat Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-11.282-0)/11.599
=-0.97

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maat Pharma  (XPAR:MAAT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Maat Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Maat Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Maat Pharma (XPAR:MAAT) Business Description

Traded in Other Exchanges
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma (XPAR:MAAT) Headlines

No Headlines